|Home | About | Journals | Submit | Contact Us | Français|
To the Editor: Multidrug-resistant tuberculosis (MDR TB), i.e., TB resistant to at least the 2 most effective first-line antituberculous drugs (isoniazid [INH] and rifampin [RIF]), is increasing globally. World Health Organization estimations of 390,000–510,000 new MDR TB cases and 150,000 related deaths in 2008 highlight the need for timely drug susceptibility testing and improved therapies (1). Although novel rapid drug susceptibility testing tools are increasingly available, their clinical applicability is unsettled. We report a patient with pulmonary TB relapse with discordant genotypic and in vitro phenotypic drug susceptibility testing results associated with a mutation outside the RIF resistance determining region (RRDR) of the rpoB gene.
In August 2009, a 45-year-old homeless woman with AIDS (CD4+ T-cell count 3 cells/mm3) and a history of substance abuse sought care for fever, night sweats, weight loss, and cough (Table A1). Pulmonary TB had been diagnosed in June 2008. At that time, she received, by directly observed therapy, 6 weeks of INH, RIF, pyrazinamide (PZA), and ethambutol (EMB) through the local health department and was switched to RIF, PZA, and EMB on week 7 after the isolate was determined by liquid culture with BD BACTEC MGIT 960 Mycobacterial Testing System (BD Diagnostics, Sparks, MD, USA) to be INH resistant. During that period, she resided in American Lung Association–supported housing for TB patients and had 97% medication adherence by dose count. Her condition clinically improved, infiltrates completely resolved according to chest radiograph, 12 sputum inductions failed to yield sufficient material for analysis, and she began highly active antiretroviral therapy (HAART). In December 2008, however, because of crack cocaine use and belligerent behavior, she lost housing privileges. Caseworkers could not locate her to complete the 9-month planned directly observed therapy.
The woman was hospitalized in January and again in February 2009 with dyspnea and off medications. In both instances, chest radiographs showed no new changes, sputum specimens were negative for acid-fast bacilli (AFB) by microscopy and culture, and she was treated for presumptive Pneumocystis pneumonia and showed clinical improvement.
In August 2009, she was readmitted with cough and new cavitation on chest radiograph. Chest computed tomographic scan demonstrated right upper lobe infiltrates, bilateral lower lobe cavitation, and hilar and mediastinal lymphadenopathy. Sputum AFB smear was positive (graded 4+), and nucleic acid amplification (Amplified Mycobacterium Direct Test; Gen-Probe, San Diego, CA, USA) was positive for Mycobacterium tuberculosis complex. INH, RIF, PZA, and EMB, along with moxifloxacin (MXF) and amikacin (AMK), were initiated in accordance with 2003 national TB treatment guidelines for possible MDR TB (2). Shortly thereafter, a line probe assay (GenoType MTBDRplus; HAIN Lifescience, Nehren, Germany) performed by Southeastern National TB Center (Gainesville, FL, USA) on the culture of the sputum specimen obtained at admission indicated an inhA point mutation but no mutation in the RRDR region of the rpoB gene, which suggested that the isolate was INH resistant but RIF susceptible. AMK was discontinued, and the patient was discharged with RIF, PZA, EMB, and MXF.
One week later, drug susceptibility testing (BD BACTEC MGIT 960 System) results from the state mycobacteriology laboratory demonstrated that the M. tuberculosis isolate was resistant to INH and RIF. The patient was readmitted to resume injectable aminoglycoside therapy. After 5 weeks, sputum culture became negative, clinical and radiographic improvement was apparent, and HAART was reinitiated. She completed 2 months’ INH/PZA/EMB/MXF/AMK inpatient therapy and was discharged to complete 6 additional months of PZA/EMB/MXF and streptomycin followed by 16 months of PZA/EMB/MFX. With HAART, her plasma HIV RNA viral load became undetectable, but her CD4 count remained low (9 cells/mm3). She died from a motor vehicle accident 10 months after recurrent TB was diagnosed.
In this patient, RIF resistance was not predicted by line probe assay but was identified phenotypically by an automated system (BD BACTEC MGIT 960 System) that continuously monitors for growth and detection of mycobacteria. Through genotyping and DNA sequencing of the 2008 and 2009 M. tuberculosis isolates, the Mycobacteriology Laboratory Branch at the Centers for Disease Control and Prevention (Atlanta, GA, USA) established that the 2009 infection was a relapse, not re-infection, and confirmed the inhA mutation in both isolates. Using primers extending beyond the RRDR (the rpoB region surveyed by rapid molecular tests and responsible for >95% of RIF resistance mutations) the laboratory identified a novel rpoB gene mutation at codon 480 (ACC→AAC; Thr→Asn) and another previously described (3–5) mutation at codon 176 (GTC→TTC; Val→Phe) in the 2009 isolate, which has been implicated in RIF resistance. The role of the T480N mutation in RIF resistance is being investigated.
This case demonstrates the limitations of rapid molecular drug susceptibility testing (6). Rapid molecular diagnostics are valuable adjuncts to conventional phenotypic testing because they can quickly confirm clinically suspected MDR TB and have high agreement with other genotypic and phenotypic methods (7–10). However, they should not supplant phenotypic testing, and clinicians should understand their limitations. When rapid molecular tests are negative but suspicion for MDR TB is high, MDR TB treatment should be continued until phenotypic susceptibility results are available. DNA sequencing may be best suited for evaluating suspected drug-resistant M. tuberculosis isolates with discordant results for phenotypic susceptibility and rapid molecular testing.
We thank Michael Leonard, Jyothi Rengarajan, Andrew Vernon, and Aliya Yamin for their assistance with this manuscript.
This work was supported by the National Institute of Health/National Institute of Allergy and Infectious Diseases (grant number T32AI074492) to A.S.K.
|May 13||Jun 2||Dec 28||Jan 31||Feb 3||Feb 24||Aug 3||Aug 4||Aug 5||Aug 19||Sep 10||Sep 11||Oct 5||Oct 7||Oct 12|
|Specimen type||Sp × 3||BAL||Sp × 3||Sp||Sp × 2||Sp × 3||Blood||Sp||Sp||Sp||Blood||Sp||Sp||Sp||Sp|
|AFB smear (MTD)||–||4+|
|4+ (MTD+)||1+||NA||1+ (MTD+)||–||–||–|
|AFB culture||–||M. tuberculosis||–||M. avium-intraceullulare||–||–||M. tuberculosis||M. tuberculosis||M. tuberculosis||M. tuberculosis, M. avium-intraceullulare||–||–||–||–||–|
|Drug susceptibility (MGIT 960)||INH resistant (0.2 μg/mL);|
RIF susceptible; EMB susceptible; STR susceptible
(0.2 μg/mL); RIF resistant; EMB susceptible; STR susceptible
|Molecular resistance testing||Sequencing:|
inhA mutation associated with INH resistance
|HAIN test: inhA point mutation; no rpoB mutation detected||CDC genotyping:|
inhA mutation associated with INH resistance + novel rpoB mutation
(2009 Sep 9)
|Drug treatment||INH/RIF/PZA/EMB initiated (2008 Jun 5)||6 mos. RIF/PZA/ EMB completed (2008 Dec 12)||INH/RIF/PZA/ EMB, AMK, MXF initiated (2009 Aug 4)||AMK stopped (2009 Sep 1)||AMK resumed (2009 Sep 9)|
*RIF, rifampin; AFB, acid-fast bacilli; sp, sputum; BAL, bronchoalveolar lavage; MTD, Mycobacterium tuberculosis Direct Test (Gen-Probe, San Diego, CA, USA); –, negative; +, positive; NA, not applicable; MGIT, BACTEC Mycobacterium Growth Indicator Testing (MGIT 960; Becton Dickinson, Franklin Lakes, NJ, USA); INH, isoniazid; RIF, rifampin; EMB, ethambutol; INH, isoniazid; STR, streptomycin; HAIN, GenoType MTBDR plus line probe assay (HAIN Lifescience, Nehren, Germany); CDC, Centers for Disease Control and Prevention (Atlanta, GA, USA); PZA, pyrazinamide; AMK, amikacin; MXF, moxifloxacin.
Suggested citation for this article: Kalokhe AS, Shafiq M, Lee JC, Metchock B, Posey JE, Ray SM, et al. Discordance in Mycobacterium tuberculosis rifampin susceptibility [letter]. Emerg Infect Dis [serial on the Internet] 2012 Mar [date cited]. http://dx.doi.org/10.3201/eid1803.111357